natgillin/translations-raw huggingface dataset:
The efficacy of Aloxi in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of a corticosteroid administered prior to chemotherapy. 
Učinkovitost zdravila Aloxi pri preprečevanju slabosti in bruhanja, povzročenih z visoko emetogenimi kemoterapijami, se poveča, če pred kemoterapijo dodamo kortikosteroid.
No pharmacokinetic data in haemodialysis patients are available. 
Za bolnike na hemodializi ni farmakokinetičnih podatkov.
500 micrograms palonosetron administered orally approximately one hour before the start of chemotherapy. 
500 mikrogramov palonosetrona damo peroralno približno eno uro pred pričetkom kemoterapije.
Although comparative efficacy of palonosetron in multiple cycles has not been demonstrated in controlled clinical trials, 217 patients were enrolled in a multicentre, open label safety study and were treated with palonosetron capsules 750 micrograms for up to 4 cycles of chemotherapy in a total of 654 chemotherapy cycles. 
Čeprav v kontroliranih kliničnih študijah niso dokazali primerjalne učinkovitosti palonosetrona v multiplih ciklusih, je bilo 217 bolnikov vključenih v multicentrično odprto študijo varnosti in so prejemali kapsule palonosetrona 750 mikrogramov v največ 4 ciklusih kemoterapije, celotno število ciklusov kemoterapije pa je bilo 654.
Most patients were non-naïve to chemotherapy (78.5%) across all treatment groups. 
Večina bolnikov (78,5 %) v vseh zdravljenih skupinah je prej že prejemala kemoterapijo.
Also contains mannitol, disodium edetate, sodium citrate, citric acid monohydrate, water for injections, sodium hydroxide and hydrochloric acid. 
Vsebuje tudi manitol, dinatrijev edetat, natrijev citrat, citronsko kislino monohidrat, vodo za injekcije, natrijev hidroksid in klorovodikovo kislino.
What Aloxi is and what it is used for What you need to know before you take Aloxi How to take Aloxi 
Kaj je zdravilo Aloxi in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Aloxi Kako uporabljati zdravilo Aloxi
A total of 493 paediatric patients, aged 64 days to 16.9 years, receiving moderately (69.2%) or highly emetogenic chemotherapy (30.8%) were treated with palonosetron 10 µg/kg (maximum 0.75 mg), palonosetron 
Vsega skupaj 493 pediatričnih bolnikov, starih od 64 dni do 16,9 let, ki so prejemali zmerno (69,2 %) ali visoko emetogeno kemoterapijo (30,8 %), so zdravili s palonosetronom 10 µg/kg (največji odmerek 0,75 mg), palonosetronom 20 µg/kg (največji odmerek 1,5 mg) ali ondansetronom
Aloxi should not be used to prevent or treat nausea and vomiting in the days following chemotherapy if not associated with another chemotherapy administration. 
Zdravilo Aloxi se ne sme uporabljati za preprečevanje ali zdravljenje navzee in bruhanja v dneh po kemoterapiji, razen če se ne uporabi zaradi dajanja naslednje kemoterapije.
No safety concerns were raised at either dose level. 
Pri nobeni stopnji odmerka ni bilo varnostnih pomislekov.
Fertility There are no data concerning the effect of palonosetron on fertility. 
Ni podatkov o vplivu palonosetrona na plodnost.
Palonosetron has been administered safely with analgesics, antiemetic/antinauseants, antispasmodics and anticholinergic medicinal products. 
Palonosetron je varen pri sočasnem jemanju z analgetiki, antiemetiki/zdravili proti slabosti,
In 12 cancer patients given a single oral dose of palonosetron capsules 500 micrograms one hour prior to chemotherapy, Cmax was 0.93 ± 0.34 ng/ml and Tmax was 5.1 ± 5.9 hours. 
Pri 12 bolnikih z rakom, ki so prejeli en sam peroralni odmerek 500-miligramskih kapsul palonosetrona eno uro pred kemoterapijo, je bila Cmax 0,93 ± 0,34 ng/ml, Tmax pa 5,1 ± 5,9 ur.
Ondansetron 32 milligrams (n= 185) 
Ondansetron 32 miligramov (n = 185)
If you stop taking Aloxi 
Če ste prenehali jemati zdravilo Aloxi
This belongs to a group of medicines called ‘serotonin (5HT3) antagonists'. 
Ta spada v skupino zdravil, ki jim pravimo »antagonisti serotoninskih 5-HT3 receptorjev«.
What Aloxi looks like and contents of the pack Aloxi solution for injection is a clear, colourless solution and is supplied in a pack of one Type I glass vial with chlorobutyl siliconised rubber stopper and aluminium cap, which contains 5 ml of the solution. 
Raztopina za injiciranje zdravila Aloxi je bistra, brezbarvna raztopina, na voljo je v pakiranju, v katerem je ena viala iz stekla tipa I z zamaškom iz klorobutilne silikonizirane gume in aluminijastim pokrovčkom, ki vsebuje 5 ml raztopine.
Type I glass vial with chlorobutyl siliconised rubber stopper and aluminium cap. 
Viala iz stekla tipa I z zamaškom iz klorobutilne silikonizirane gume in aluminijastim pokrovčkom.
Tell your doctor straight away if you notice any of the following serious side effects: 
Takoj obvestite zdravnika, če opazite katerega koli od naslednjih resnih neželenih učinkov:
Palonosetron is a selective high-affinity receptor antagonist of the 5HT3 receptor. 
Palonosetron je selektiven antagonist 5-HT3 receptorjev z veliko afiniteto.
There are limited data on the use of Aloxi in the prevention of nausea and vomiting in children under 2 years of age. 
Podatkov o uporabi zdravila Aloxi za preprečevanje navzee in bruhanja pri otrocih,
• hiccups, passing wind (flatulence), dry mouth or indigestion 
• kolcanje, vetrovi (flatulenca), suha usta ali slaba prebava,
Palonosetron is mainly metabolised by CYP2D6, with minor contribution by CYP3A4 and CYP1A2 isoenzymes. 
Palonosetron večinoma metabolizira encim CYP2D6, nekaj pa tudi izoencima CYP3A4 in CYP1A2.
No data are available for patients with end stage renal disease undergoing haemodialysis. 
Ni podatkov za bolnike s končno ledvično okvaro na hemodializi.
Emetogenic chemotherapies administered included doxorubicin, cyclophosphamide (<1500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, and daunorubicin. 
ciklofosfamid (<1500 mg/m2), ifosfamid, cisplatin, daktinomicin, karboplatin in davnorubicin.
≤1,500 mg/m2 and doxorubicin >25 mg/m2, palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg (half-life 4 hours) or dolasetron 100 mg (half-life 7.3 hours) administered intravenously on Day 1, without dexamethasone. 
≤1500 mg/m2 in doksorubicin >25 mg/m2, so primerjali odmerka palonosetrona 250 mikrogramov in 750 mikrogramov v primerjavi z ondansetronom 32 mg (razpolovni čas 4 ure) ali dolasetronom 100 mg (razpolovni čas 7,3 ure), danih intravensko prvi dan kemoterapije, brez deksametazona.
The primary efficacy variable was the proportion of patients with a complete response (CR, defined as no emetic episode and no rescue medication) during the first 24 hours after the start of chemotherapy administration. 
Primarna spremenljivka učinkovitosti je bilo razmerje bolnikov s popolnim odgovorom (opredeljen kot brez bruhanja in dodatnega zdravila) v prvih 24 urah po uvedbi kemoterapije.
Efficacy was based on demonstrating non-inferiority of oral palonosetron doses compared to the approved intravenous formulation. 
Učinkovitost je temeljila na dokazu ne-manjvrednosti peroralnih odmerkov palonosetrona v primerjavi z odobrenim intravenskim pripravkom.
24 - 120 hours 0 - 120 hours a Intent-to-treat cohort. 
24 - 120 ur 0 - 120 ur a Kohorta z namenom zdravljenja.
Aloxi capsules may also contain a trace of lecithin derived from soya. 
Kapsule zdravila Aloxi lahko v sledovih vsebujejo lecitin iz soje.
• The other ingredients are glycerol monocaprylocaproate (type I), polyglycerol oleate, glycerol, 
• Druge sestavine zdravila so glicerol monokaprilat monokaprinat (tip I), poliglicerol oleat, glicerol,
What you need to know before you take Aloxi 
Kaj morate vedeti, preden boste vzeli zdravilo Aloxi
• The other ingredients are mannitol, disodium edetate, sodium citrate, citric acid monohydrate, water for injections, sodium hydroxide and hydrochloric acid. 
• Druge sestavine zdravila so manitol, dinatrijev edetat, natrijev citrat, citronska kislina monohidrat, voda za injekcije, natrijev hidroksid in klorovodikova kislina.
After a single intravenous bolus administration in healthy subjects the total body clearance of palonosetron was 173 ± 73 ml/min and renal clearance was 53 ± 29 ml/min. 
Po enkratnem intravenskem bolusu danem zdravim preiskovancem je očistek palonosetrona 173 ± 29 ml/min in ledvični očistek 53 ± 29 ml/min.
Given the pre-specified non-inferiority margin of -10%, the stratum adjusted Mantel-Haenszel statistical non-inferiority confidence interval for the difference in the primary endpoint, complete response (CR), was [-10.5, 1.7%], therefore non-inferiority was not demonstrated. 
Ob vnaprej določeni meji ne-manjvrednosti, ki je bila -10 %, je bil Mantel-Haenszlov statistični ne-manjvrednostni interval zaupanja s prilagojeno stratifikacijo za razliko v primarnem kriteriju, popolnem odgovoru (CR), [-10,5, 1,7 %], kar pomeni, da ne-manjvrednost ni bila dokazana.
Breast-feeding It is not known if Aloxi is found in breast milk. 
Dojenje Ni znano, ali zdravilo Aloxi prehaja v materino mleko.
There have been reports of serotonin syndrome with the use of 5-HT3 antagonists either alone or in combination with other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs). 
Pri uporabi antagonistov serotoninskih 5-HT3 receptorjev, bodisi samih bodisi skupaj z drugimi serotoninergičnimi zdravili (vključno s selektivnimi zaviralci privzema serotonina (SSRI) in zaviralci privzema serotonina in noradrenalina (SNRI)), so poročali o serotoninskem sindromu.
Table 2: Pharmacokinetic Parameters in Paediatric Cancer Patients following intravenous infusion of Aloxi at 20 µg/kg over 15 min and in Adult Cancer Patients receiving 3 and 10 µg/kg palonosetron doses via intravenous bolus. 
Farmakokinetični parametri pri pediatričnih bolnikih z rakom po intravenski infuziji zdravila Aloxi s hitrostjo 20 µg/kg v času 15 min in pri odraslih bolnikih z rakom, ki so prejeli odmerka 3 in 10 µg/kg palonosetrona v obliki intravenskega bolusa.
The objective was to evaluate the ECG effects of IV administered palonosetron at single doses of 0.25, 0.75 or 2.25 mg in 221 healthy subjects. 
danega palonosetrona v enkratnih odmerkih po 0,25, 0,75 ali 2,25 mg na EKG pri 221 zdravih osebah.
As palonosetron may increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored following administration. 
Ker palonosetron lahko podaljša čas prehoda skozi široko črevo, je potrebno bolnike, ki so zaprti ali so imeli subakutno obstrukcijo črevesja, po dajanju palonosetrona spremljati.
The highest dose group showed a similar incidence of adverse reactions compared to the other dose groups and no dose response effects were observed. 
V skupini z največjim odmerkom je bila pogostost neželenih učinkov podobna kot pri skupinah z drugimi odmerki.
Aloxi is indicated in adults for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. 
Zdravilo Aloxi je indicirano pri odraslih za preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenimi kemoterapijami pri zdravljenju raka.
After single oral doses using buffered solution mean maximum palonosetron concentrations (Cmax) and area under the concentration-time curve (AUC0-∞) were dose proportional over the dose range of 3.0 to 80 µg/kg in healthy subjects. 
Po enkratnih peroralnih odmerkih z uporabo raztopine z uravnavanim pH so bile srednje najvišje koncentracije palonosetrona (Cmax) in površina pod krivuljo koncentracija-čas (AUC0-∞) pri zdravih osebah sorazmerne odmerku v mejah odmerkov med 3,0 in 80 µg/kg.
Hyperkalaemia, metabolic disorders, hypocalcaemia, hypokalaemia, anorexia, hyperglycaemia, appetite decreased 
Presnovne in prehranske motnje hiperkaliemija, presnovne motnje, hipokalciemija, hipokaliemija, anoreksija, hiperglikemija, zmanjšanje apetita
• Do not use this medicine after the expiry date which is stated on the blister and carton after 
• Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake ''EXP".
It is not recommended to take Aloxi in the days following chemotherapy unless you are going to have another chemotherapy cycle. 
Jemanja zdravila Aloxi v dnevih po kemoterapiji se ne priporoča, razen če boste imeli še en cikel kemoterapije.
• numbness, burning, prickling or tingling sensations on the skin 
• odrevenelost, občutek pečenja, zbadanja ali mravljinčenja na koži,
This is very rare: may affect up to 
To je zelo redko: lahko se pojavi pri manj kot 1
ondansetron regimen. 
shemo odmerjanja ondansetrona.
At all dose levels tested, palonosetron did not induce clinically relevant prolongation of the QTc interval. 
V vseh preskušanih odmerkih palonosetron ni induciral klinično pomembnega podaljšanja korigiranega intervala QT.
250 micrograms palonosetron administered as a single intravenous bolus approximately 30 minutes before the start of chemotherapy. 
Odmerek 250 mikrogramov palonosetrona dajemo kot enkratni intravenski bolus približno 30 minut pred pričetkom kemoterapije.
Palonosetron is not mutagenic. 
Palonosetron ni mutagen.
Since palonosetron may induce dizziness, somnolence or fatigue, patients should be cautioned when driving or operating machines. 
Ker lahko palonosetron povzroči omotico, zaspanost ali utrujenost, je treba bolnike, ki vozijo ali upravljajo s stroji, opozoriti na te učinke.
Corticosteroids Palonosetron has been administered safely with corticosteroids. 
Palonosetron je varen pri sočasni uporabi s kortikosteroidi.
In vitro metabolism studies have shown that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 isoenzymes are involved in the metabolism of palonosetron. 
Študije metabolizma in vitro so pokazale, da so v metabolizem palonosetrona vključeni CYP2D6 in v manjši meri CYP3A4 in CYP1A2 izoencimi.
Non-inferiority criteria were met if the lower bound of the 97.5% confidence interval for the difference in Complete Response rates of intravenous palonosetron minus intravenous ondansetron was larger than -15%. 
Kriteriji ne-manjvrednosti so bili izpolnjeni, če je bila spodnja meja 97,5-odstotnega intervala za razliko med pogostnostjo popolnega odziva pri intravenskem palonosetronu in pri intravenskem ondansetronu večja kot -15 %.
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking Aloxi. 
Če za vas velja kar koli od zgoraj navedenega (ali pa niste prepričani), se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Aloxi.
High doses of palonosetron (each dose causing at least 30 times the human therapeutic exposure) applied daily for two years caused an increased rate of liver tumours, endocrine neoplasms (in thyroid, pituitary, pancreas, adrenal medulla) and skin tumours in rats but not in mice. 
Visoki odmerki palonosetrona (vsak odmerek 30 krat večji od človeškega terapevtskega odmerka) apliciranih dnevno v obdobju dveh let, so povzročili povišano pojavljanje jetrnih tumorjev, endokrinih neoplazem (v ščitnici, hipofizi, trebušni slinavki in sredici nadledvičnice)
If you are not sure, talk to your doctor or pharmacist before taking this medicine. 
Če niste prepričani, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Aloxi 500 micrograms soft capsules Palonosetron 
Aloxi 500 mikrogramov mehke kapsule palonosetron
Complete Control (Complete Response and No More Than Mild Nausea) p-value c 
Popolna kontrola (popoln odziv in kvečjemu blaga navzea)
Very rare (<1/10,000) adverse reactions were reported post-marketing. 
V študijah po prihodu zdravila na trg so poročali o zelo redkih (<1/10.000) neželenih učinkih.
0 - 24 hours 
0 - 24 ur
AUC0-∞, h·µg/L 
Očistek c, l/h/kg
Citric acid monohydrate Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections 
6.1 Seznam pomožnih snovi manitol dinatrijev edetat natrijev citrat citronska kislina monohidrat natrijev hidroksid (za uravnavanje pH) klorovodikova kislina (za uravnavanje pH) voda za injekcije
• high levels of the pigment bilirubin in the blood 
• visoka koncentracija bilirubina v krvi,
• headache, feeling dizzy, 
• glavobol, občutek omotičnosti,
• The active substance is palonosetron (as hydrochloride). 
• Učinkovina je palonosetron (v obliki palonosetronijevega klorida).
20 µg/kg (maximum 1.5 mg) or ondansetron (3 x 0.15 mg/kg , maximum total dose 32 mg) 30 minutes prior to the start of emetogenic chemotherapy during Cycle 1. 
(3 x 0,15 mg/kg , največji celotni odmerek 32 mg) 30 minut pred začetkom emetogene kemoterapije med ciklom 1.
Medicines for depression or anxiety Tell your doctor or pharmacist if you are taking any medicines for depression or anxiety, including: 
Obvestite zdravnika ali farmacevta, če jemljete katera koli zdravila za depresijo ali anksioznost, vključno z:
• abnormal heart rate or lack of blood flow to the heart 
• zvišan ali znižan krvni tlak, • nenormalna frekvenca srca ali premajhen dotok krvi v srce,
Table 2: Percentage of patients a responding by treatment group and phase in the Moderately Emetogenic Chemotherapy study versus dolasetron Aloxi 250 micrograms (n= 185) 
Preglednica 2: Odstotek bolnikova, ki reagirajo na zdravljenje, glede na vrsto zdravljenja in stopnjo zdravljenja v študiji zmerno emetogene kemoterapije v primerjavi z dolasetronom Aloxi 250 mikrogramov (n = 185)
If you are not sure, talk to your doctor or nurse before you are given this medicine. 
Če niste prepričani, se posvetujte z zdravnikom ali medicinsko sestro, preden prejmete to zdravilo.
METHOD OF ADMINISTRATION Read the package leaflet before use 
POSTOPEK UPORABE Pred uporabo preberite priloženo navodilo.
Pharmacotherapeutic group: Antiemetics and antinauseants, serotonin (5HT3) antagonists. 
Farmakoterapevtska skupina: Antiemetiki in zdravila proti slabosti, antagonisti serotoninskih 5-HT3 receptorjev.
Dexamethasone was administered prophylactically before chemotherapy in 67 % of patients. 
67 % bolnikov je prejemalo deksametazon profilaktično pred kemoterapijo.
• the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. 
• preprečevanje akutne slabosti in bruhanja, povezanih z visoko emetogenimi kemoterapijami pri zdravljenju raka in preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenimi kemoterapijami pri zdravljenju raka.
Dermatitis allergic, pruritus, skin disorder, urticaria 
Bolezni kože in podkožja alergijski dermatitis, pruritus, kožna bolezen, koprivnica
High doses of palonosetron (each dose causing at least 15 times the human therapeutic exposure) applied daily for two years caused an increased rate of liver tumours, endocrine neoplasms (in thyroid, pituitary, pancreas, adrenal medulla) and skin tumours in rats but not in mice. 
Veliki odmerki palonosetrona (vsak odmerek 15-krat večji od človeškega terapevtskega odmerka), aplicirani dnevno v obdobju dveh let, so povzročili zvečano pojavljanje jetrnih tumorjev, endokrinih neoplazem (v ščitnici, hipofizi, trebušni slinavki in sredici nadledvičnice)
Aloxi 250 micrograms (n= 189) 
Aloxi 250 mikrogramov (n = 189)
Age does not affect the pharmacokinetics of palonosetron. 
Starost ne vpliva na farmakokinetiko palonosetrona.
Electrocardiogram QT prolonged conduction disorder, sinus tachycardia 
Srčne bolezni podaljšanje intervala QT v elektrokardiogramu prevodna motnja, sinusna tahikardija
In healthy subjects given palonosetron capsules 500 micrograms, the terminal elimination half-life (t½) of palonosetron was 37 ± 12 hours (mean ± SD), and in cancer patients, t½ was 48 ± 19 hours. 
500 mikrogramov, je bil končni razpolovni čas odstranjevanja palonosetrona iz telesa (t½) 37 ± 12 ur (povprečje ± SD), pri bolnikih z rakom pa 48 ± 19 ur.
0-24 hours 
0-24 ur
• fever 
• vročina,
Aloxi contains sodium 
Zdravilo Aloxi vsebuje natrij
• the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, 
• preprečevanje akutne slabosti in bruhanja, povezanih z visoko emetogenimi kemoterapijami pri zdravljenju raka,
Gender does not affect the pharmacokinetics of palonosetron. 
Spol bolnika ne vpliva na farmakokinetiko palonosetrona.
It is not recommended you are given Aloxi in the days following chemotherapy unless you are going to have another chemotherapy cycle. 
Dajanja zdravila Aloxi v dnevih po kemoterapiji se ne priporoča, razen če boste imeli še en cikel kemoterapije.
Tachycardia, bradycardia, extrasystoles, myocardial ischaemia, sinus tachycardia, sinus arrhythmia, supraventricular extrasystoles 
Srčne bolezni tahikardija, bradikardija, prezgodnji utripi, miokardna ishemija, sinusna tahikardija, sinusna aritmija, nadprekatni prezgodnji utripi
A lower bound greater than -15 % demonstrates non-inferiority between Aloxi and comparator. 
Spodnja meja višja od -15 % dokazuje nemanjvrednost zdravila Aloxi proti primerjanemu zdravilu.
p-value c 
p-vrednostc
Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects. 
Jetrna okvara v primerjavi z zdravimi preiskovanci ne vpliva pomembno na celotni očistek palonosetrona.
• The active substance is palonosetron. 
• Učinkovina je palonosetron.
• abnormal heart rate 
• nenormalen srčni utrip,
The safety and efficacy of Palonosetron i.v at single doses of 1µg/kg and 3µg/kg was compared in the first clinical study in 150 patients in the following age groups, >28 days to 23 months (7 patients), 2 to 11 years (96 patients), and 12 to 16 years of age (47 patients) undergoing elective surgery. 
pri enojnem odmerku 1 µg/kg in 3 µg/kg so primerjali v prvi klinični študiji s 150 bolniki v naslednjih starostnih skupinah: > 28 dni do 23 mesecev (7 bolnikov), 2 do 11 let (96 bolnikov) in 12 do 16 let (47 bolnikov) z elektivno operacijo.
Tell your doctor straight away if you notice any of the serious side effects listed above. 
Takoj obvestite zdravnika, če opazite katerega koli od zgoraj navedenih resnih neželenih učinkov.
See package leaflet for further information. 
Za nadaljnje podatke glejte navodilo za uporabo.
0 - 120 hours 
0 - 120 ur
In the clinical studies the following adverse reactions (ARs) were observed as possibly or probably related to Aloxi. 
V kliničnih študijah so opažali naslednje neželene učinke, ki jih je mogoče pripisati jemanju zdravila Aloxi.
Non-clinical studies indicate that palonosetron, only at very high concentrations, may block ion channels involved in ventricular de- and re-polarisation and prolong action potential duration. 
Predklinične študije kažejo na to, da palonosetron lahko blokira ionske kanalčke udeležene pri ventrikularni de in repolarizaciji, ter s tem podaljša trajanje akcijskega potenciala le v zelo visokih koncentracijah.
The safety and efficacy of Palonosetron i.v at single doses of 3 µg/kg and 10 µg/kg was investigated in the first clinical study in 72 patients in the following age groups, >28 days to 23 months (12 patients), 2 to 11 years (31 patients), and 12 to 17 years of age (29 patients), receiving highly or moderately emetogenic chemotherapy. 
pri enojnem odmerku 3 µg/kg in 10 µg/kg so raziskovali v prvi klinični študiji z 72 bolniki v naslednjih starostnih skupinah: >28 dni do 23 mesecev (12 bolnikov), 2 do 11 let (31 bolnikov) in 12 do 17 let (29 bolnikov), ki so prejemali zelo ali zmerno emetogeno kemoterapijo.
Musculoskeletal and connective tissue disorders 
Bolezni mišično-skeletnega sistema in vezivnega tkiva artralgija
Hypersensitivity, anaphylaxis, anaphylactic/ anaphylactoid reactions and shock 
anafilaktične/anafil aktoidne reakcije in šok
What you need to know before you are given Aloxi 
Kaj morate vedeti, preden boste prejeli zdravilo Aloxi
24-120 hours 
24-120 ur
Hypotension, hypertension, vein discolouration, vein distended 
Žilne bolezni hipotenzija, hipertenzija, vensko razbarvanje, razširitev ven
However, as for other 5-HT3 antagonists, caution should be exercised in the use of palonosetron in patients who have or are likely to develop prolongation of the QT interval. 
Toda, kot pri drugih antagonistih 5-HT3 je potrebna previdnost pri uporabi palonosetrona pri bolnikih,